What do you consider "sorafenib failure?" Progression on radiological evaluation, clinical evaluation, or both?

Thomas A. Abrams, MD: Clinical deterioration that is not related to obvious AEs of sorafenib has to be regarded as a progression or sorafenib failure, especially if there's corroborating evidence such as biochemical worsening, AFPs going up, worsening liver function, or ascites. Those could be used as a surrogate to progression. If radiological data suggest that the disease is getting worse with new or enlarged lesions, worsening portal venous thrombus, or worsening liver function due to increas...

Continue reading

Hepatocellular Carcinoma: Current Challenges and Future Directions With Thomas A. Abrams, MD

Hepatocellular carcinoma (HCC) is the sixth most common tumor globally. Patients with HCC have a dismal prognosis, with a 5-year survival rate of 18%. Thomas A. Abrams, MD, assistant professor of medicine at Harvard Medical School, spoke with i3 Health about how strong physician-patient relationships and a multidisciplinary approach can facilitate the management of HCC and improve outcomes.  

Continue reading

Cabozantinib in Hepatocellular Carcinoma: An Interview With Thomas A. Abrams, MD

​Hepatocellular carcinoma (HCC), the most common type of primary liver cancer, is a challenging condition to treat, with reported five-year survival rates ranging from 30% to 50%. Recently, the FDA approved cabozantinib (Cabometyx®, Exelixis, Inc.) as second-line treatment for patients with HCC previously treated with sorafenib. Thomas A. Abrams, MD, Assistant Professor of Medicine at Harvard Medical School, spoke with i3 Health about cabozantinib's approval and about the various options now ava...

Continue reading

Copyright © 2022 Oncology Data Advisor. All rights reserved.